Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation
L Peng, Z Song, S Jiao - OncoTargets and therapy, 2015 - Taylor & Francis
Non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation is
sensitive to EGFR tyrosine kinase inhibitors (TKIs). But little is known about the response to …
sensitive to EGFR tyrosine kinase inhibitors (TKIs). But little is known about the response to …
Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
JY Wu, JY Shih - OncoTargets and therapy, 2016 - Taylor & Francis
Background Clinical features of epidermal growth factor receptor (EGFR) mutations: L858R,
deletions in exon 19, T790M, insertions in exon 20, G719X, and L861X in non-small-cell …
deletions in exon 19, T790M, insertions in exon 20, G719X, and L861X in non-small-cell …
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations
L Peng, ZG Song, SC Jiao - Scientific reports, 2014 - nature.com
The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
K Chen, X Yu, H Wang, Z Huang, Y Xu, L Gong… - Cancer Chemotherapy …, 2017 - Springer
Purpose Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
Treatment strategies for non-small cell lung cancer harboring common and uncommon EGFR mutations: drug sensitivity based on exon classification, and structure …
R Kitadai, Y Okuma - Cancers, 2022 - mdpi.com
Simple Summary The advent of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …
Clinicopathologic characteristics and outcome of patients with different EGFR mutations
S Zhou, X Hu, Y Wang, J Li, L Zhou… - Asia‐Pacific Journal …, 2019 - Wiley Online Library
Aim Most epidermal growth factor receptor (EGFR) gene mutations affecting exon 19
(inframe deletions; 19 Del) and 21 (L858R), while the rest (referred as uncommon EGFR …
(inframe deletions; 19 Del) and 21 (L858R), while the rest (referred as uncommon EGFR …
Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
D Chen, Z Song, G Cheng - OncoTargets and therapy, 2016 - Taylor & Francis
Purpose Subsets of non-small-cell lung cancer patients with epidermal growth factor
receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first …
receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first …
[HTML][HTML] Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes
T John, A Taylor, H Wang, C Eichinger, C Freeman… - Cancer …, 2022 - Elsevier
Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …
[HTML][HTML] Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients
J Su, W Zhong, X Zhang, Y Huang, H Yan, J Yang… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Patients with non-small cell lung cancer (NSCLC) with activating epidermal growth factor
receptor (EGFR) mutations (exon 19 deletions and L858R) benefit from EGFR tyrosine …
receptor (EGFR) mutations (exon 19 deletions and L858R) benefit from EGFR tyrosine …
[HTML][HTML] Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer
H Jiang, M Zhu, Y Li, Q Li - Molecular and clinical …, 2019 - spandidos-publications.com
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI) is the first‑line
treatment for patients with advanced non‑small‑cell lung cancer (NSCLC) who have an …
treatment for patients with advanced non‑small‑cell lung cancer (NSCLC) who have an …
相关搜索
- egfr exon survival rates
- egfr mutations outcome of patients
- egfr exon lung cancer
- egfr exon nsclc patients
- egfr mutations treatment strategies
- egfr exon clinical outcomes
- egfr mutations efficacy analysis
- egfr mutations clinicopathologic characteristics
- egfr exon molecular characteristics
- egfr mutations drug sensitivity
- egfr mutations lung cancer
- egfr mutations clinical outcomes
- egfr exon clinical efficacy